» Articles » PMID: 10574912

Cyclin K Functions As a CDK9 Regulatory Subunit and Participates in RNA Polymerase II Transcription

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Nov 27
PMID 10574912
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Important progress in the understanding of elongation control by RNA polymerase II (RNAPII) has come from the recent identification of the positive transcription elongation factor b (P-TEFb) and the demonstration that this factor is a protein kinase that phosphorylates the carboxyl-terminal domain (CTD) of the RNAPII largest subunit. The P-TEFb complex isolated from mammalian cells contains a catalytic subunit (CDK9), a cyclin subunit (cyclin T1 or cyclin T2), and additional, yet unidentified, polypeptides of unknown function. To identify additional factors involved in P-TEFb function we performed a yeast two-hybrid screen using CDK9 as bait and found that cyclin K interacts with CDK9 in vivo. Biochemical analyses indicate that cyclin K functions as a regulatory subunit of CDK9. The CDK9-cyclin K complex phosphorylated the CTD of RNAPII and functionally substituted for P-TEFb comprised of CDK9 and cyclin T in in vitro transcription reactions.

Citing Articles

Deriving general structure-activity/selectivity relationship patterns for different subfamilies of cyclin-dependent kinase inhibitors using machine learning methods.

Kaveh S, Mani-Varnosfaderani A, Neiband M Sci Rep. 2024; 14(1):15315.

PMID: 38961127 PMC: 11222421. DOI: 10.1038/s41598-024-66173-z.


RNet: a network strategy to predict RNA binding preferences.

Liu H, Jian Y, Hou J, Zeng C, Zhao Y Brief Bioinform. 2023; 25(1).

PMID: 38145947 PMC: 10749790. DOI: 10.1093/bib/bbad482.


CDK11 facilitates centromeric transcription to maintain centromeric cohesion during mitosis.

Zhang Q, Chen Y, Teng Z, Lin Z, Liu H Mol Biol Cell. 2023; 35(2):ar18.

PMID: 38019613 PMC: 10881149. DOI: 10.1091/mbc.E23-08-0303.


Coming of Age: Targeting Cyclin K in Cancers.

Xiao Y, Dong J Cells. 2023; 12(16).

PMID: 37626854 PMC: 10453554. DOI: 10.3390/cells12162044.


Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.

Xiao L, Liu Y, Chen H, Shen L Cancer Biol Ther. 2023; 24(1):2219470.

PMID: 37272701 PMC: 10243401. DOI: 10.1080/15384047.2023.2219470.